دورية أكاديمية
R‐DHA‐oxaliplatin (R‐DHAOx) versus R‐DHA‐cisplatin (R‐DHAP) regimen in B‐cell lymphoma treatment: A eight‐year trajectory study
| العنوان: | R‐DHA‐oxaliplatin (R‐DHAOx) versus R‐DHA‐cisplatin (R‐DHAP) regimen in B‐cell lymphoma treatment: A eight‐year trajectory study |
|---|---|
| المؤلفون: | Lacout, Carole, Orvain, Corentin, Seegers, Valérie, de Vries, Manon, Mercier, Mélanie, Farhi, Jonathan, Clavert, Aline, Thepot, Sylvain, Moles, Marie‐pierre, Ifrah, Norbert, Hunault‐berger, Mathilde, Schmidt, Aline |
| المساهمون: | Service des maladies du sang CHU Angers, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), Université d'Angers (UA)-Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Innate Immunity and Immunotherapy (CRCINA-ÉQUIPE 7), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE) |
| المصدر: | ISSN: 0902-4441. |
| بيانات النشر: | HAL CCSD Wiley |
| سنة النشر: | 2020 |
| المجموعة: | Université de Nantes: HAL-UNIV-NANTES |
| مصطلحات موضوعية: | Non-Hodgkin lymphoma, nephrotoxicity, platinum, trajectories, [SDV.CAN]Life Sciences [q-bio]/Cancer |
| الوصف: | International audience ; Background: The R-DHAP regimen (rituximab, cisplatin, dexamethasone, and high-dose cytarabine) is standardly used to treat relapsed Non-Hodgkin lymphoma (NHL). Despite scarce data, cisplatin is frequently substituted with oxaliplatin (R-DHAOx) to avoid nephrotoxicity. We compared nephrotoxicity of cisplatin and oxaliplatin based on creatinine-based trajectory modeling.Methods: All patients with NHL treated by R-DHAP or R-DHAOx in Angers hospital between January 01, 2007, and December 31, 2014, were included. Patients received cisplatin 100 mg/m2 or oxaliplatin 130 mg/m2 (d1) with cytarabine (2000 mg/m2 , two doses, d2), dexamethasone (40 mg, d1-4), and rituximab (375 mg/m2 , d1). Creatinine levels were recorded before each cycle. Individual profiles of trajectories were clustered to detect homogeneous patterns of evolution.Results: Twenty-two patients received R-DHAP, 35 R-DHAOx, 6 switched from R-DHAP to R-DHAOx due to nephrotoxicity. Characteristics of patients were similar between two groups. Patients receiving R-DHAP experienced more severe renal injury than patients receiving R-DHAOx (68% vs. 7.7%, P < .001). Two homogeneous clusters appeared: cluster A, with a majority of R-DHAOx (32, 91.4%), was less nephrotoxic than B, with a majority of R-DHAP (19, 86.4%), with a decreased average serum creatinine level (P < .0001). There were no other differences between clusters.Conclusions: Our study confirms that R-DHAOx regimen causes less nephrotoxicity than R-DHAP regimen. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/32302426; inserm-03498857; https://inserm.hal.science/inserm-03498857Test; https://inserm.hal.science/inserm-03498857/documentTest; https://inserm.hal.science/inserm-03498857/file/European%20J%20of%20Haematology%20-%202020%20-%20Lacout%20-%20R%E2%80%90DHA%E2%80%90oxaliplatin%20%20R%E2%80%90DHAOx%20%20versus%20R%E2%80%90DHA%E2%80%90cisplatin%20%20R%E2%80%90DHAP%20%20regimen%20in%20B%E2%80%90cell.pdfTest; PUBMED: 32302426 |
| DOI: | 10.1111/ejh.13429 |
| الإتاحة: | https://doi.org/10.1111/ejh.13429Test https://inserm.hal.science/inserm-03498857Test https://inserm.hal.science/inserm-03498857/documentTest https://inserm.hal.science/inserm-03498857/file/European%20J%20of%20Haematology%20-%202020%20-%20Lacout%20-%20R%E2%80%90DHA%E2%80%90oxaliplatin%20%20R%E2%80%90DHAOx%20%20versus%20R%E2%80%90DHA%E2%80%90cisplatin%20%20R%E2%80%90DHAP%20%20regimen%20in%20B%E2%80%90cell.pdfTest |
| رقم الانضمام: | edsbas.5E5FA7DF |
| قاعدة البيانات: | BASE |
| DOI: | 10.1111/ejh.13429 |
|---|